Curanex Pharmaceuticals Inc
CURXNasdaqHealthcare · Pharmaceutical Preparations · NV · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | |
|---|---|---|
| Revenue | — | — |
| Operating income | −$4.2M | −$365,062 |
| Net income | −$4.2M | −$361,506 |
| Total assets | $11.6M | $517,935 |
| Total liabilities | $361,040 | $14,575 |
| Equity | $11.2M | $503,360 |
| EPS (diluted) | $-0.17 | $-0.03 |
| Shares out. | 28.3M | 24.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −37.7%
- Return on assets
- −36.5%
- Return on capital (ROCE)
- −37.0%
- Liabilities / assets
- 3.1%
- Debt / equity
- 0.03×
- Book value / share
- $0.40
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 35.09safe
- Accruals / assets
- 54.1%high accruals
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 2 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 17, 2025
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 37,251 | 1.0 | -21.8% |
| Apr 30, 2026 | 47,658 | 1.0 | -6.5% |
| Apr 15, 2026 | 50,975 | 1.0 | -52.4% |
| Mar 31, 2026 | 107,154 | 1.0 | -74.4% |
| Mar 13, 2026 | 418,898 | 1.0 | -88.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosureMay 14, 2026
- Other material eventMay 7, 2026
- Regulation FD disclosureApr 2, 2026
- Entered a material agreement · Director / officer changeMar 6, 2026
- Director / officer changeJan 5, 2026
- Delisting / listing-standard noticeNov 6, 2025
- Unregistered equity sale · Other material eventSep 29, 2025
- Other material eventSep 12, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.